ITeos, GSK discontinue lung cancer therapy development
13/05/2025 13:12
May 13 (Reuters) - iTeos Therapeutics ITOS.O and partner GSK GSK.L said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival in a mid-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D'Silva) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive